BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 5.04

Change

+0.00 (+0.05)%

Market Cap

N/A

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNIF:LSE Xtrackers Nifty 50 Swap UCITS ..

+151.00 (+0.80%)

USD 292,109.69B
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+5.35 (+2.23%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

-6.50 (-3.07%)

USD 1,607.29B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.38 (+2.13%)

USD 701.81B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.14 (+0.96%)

USD 636.56B
0R1I:LSE NVIDIA Corp.

+2.48 (+2.21%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-1.25 (-1.75%)

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

+0.68 (+2.27%)

USD 260.39B
0QZO:LSE 0QZO

-0.30 (-0.28%)

USD 258.54B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.09% 54% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.09% 52% F 52% F
Trailing 12 Months  
Capital Gain -0.25% 23% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.25% 20% F 34% F
Trailing 5 Years  
Capital Gain -98.75% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.75% 2% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -3.50% 12% F 23% F
Dividend Return -3.50% 11% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.22% 24% F 39% F
Risk Adjusted Return -13.89% 15% F 25% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.